Cosopt Related Published Studies
Well-designed clinical trials related to Cosopt (Dorzolamide / Timolol Ophthalmic)
Dorzolamide/Timolol fixed combination versus latanoprost/timolol fixed combination in patients with primary open-angle glaucoma or ocular hypertension. [2008.02]
Comparison of the 24-hour intraocular pressure-lowering effects of latanoprost and dorzolamide/timolol fixed combination after 2 and 6 months of treatment. [2008.01]
Comparing the fixed combination brimonidine-timolol versus fixed combination dorzolamide-timolol in patients with elevated intraocular pressure. [2007.04]
A comparison of travoprost, latanoprost, and the fixed combination of dorzolamide and timolol in patients with pseudoexfoliation glaucoma. [2006.01]
A randomized trial assessing dorzolamide in patients with glaucoma who are younger than 6 years. [2005.09]
Efficacy of the dorzolamide/timolol fixed combination versus latanoprost in the treatment of ocular hypertension or glaucoma: combined analysis of pooled data from two large randomized observer and patient-masked studies. [2005.06]
Safety and efficacy of bimatoprost 0.03% versus timolol maleate 0.5%/dorzolamide 2% fixed combination. [2005.05]
Comparing the fixed combination dorzolamide-timolol (Cosopt) to concomitant administration of 2% dorzolamide (Trusopt) and 0.5% timolol -- a randomized controlled trial and a replacement study. [2004.08]
Effects on aqueous flow of dorzolamide combined with either timolol or acetazolamide. [2004.06]
Dorzolamide/Timolol fixed combination versus concomitant administration of brimonidine and timolol in patients with elevated intraocular pressure: a 3-month comparison of efficacy, tolerability, and patient-reported measures. [2004.04]
Efficacy and tolerability of the dorzolamide 2%/timolol 0.5% combination (COSOPT) versus 0.005% (XALATAN) in the treatment of ocular hypertension or glaucoma: results from two randomized clinical trials. [2004.02]
Efficacy and safety of the fixed combinations latanoprost/timolol versus dorzolamide/timolol in patients with elevated intraocular pressure. [2004.02]
A 3-month randomized controlled trial of bimatoprost (LUMIGAN) versus combined timolol and dorzolamide (Cosopt) in patients with glaucoma or ocular hypertension. [2003.12]
Effect of a fixed dorzolamide-timolol combination on intraocular pressure after small-incision cataract surgery with Viscoat. [2003.09]
Unoprostone as adjunctive therapy to timolol: a double masked randomised study versus brimonidine and dorzolamide. [2003.05]
Dorzolamide/timolol combination versus concomitant administration of brimonidine and timolol: six-month comparison of efficacy and tolerability. [2003.03]
Timolol 0.5%/dorzolamide 2% fixed combination vs timolol maleate 0.5% and unoprostone 0.15% given twice daily to patients with primary open-angle glaucoma or ocular hypertension. [2003.02]
Tolerability and efficacy of dorzolamide versus acetazolamide added to timolol. [2002.06]
Effects of timolol and dorzolamide on retrobulbar hemodynamics in patients with newly diagnosed primary open-angle glaucoma. [2002.03]
Effect of dorzolamide timolol combination versus timolol 0.5% on ocular bloodflow in patients with primary open-angle glaucoma. [2001.10]
Comparison of the additive intraocular pressure-lowering effect of latanoprost and dorzolamide when added to timolol in patients with open-angle glaucoma or ocular hypertension: a randomized, open-label, multicenter study in Greece. [2001.08]
Comparison of topical brinzolamide 1% and dorzolamide 2% eye drops given twice daily in addition to timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension. [2001.08]
Intraindividual comparison of the effects of a fixed dorzolamide-timolol combination and latanoprost on intraocular pressure after small incision cataract surgery. [2001.05]
Latanoprost versus combined therapy with timolol plus dorzolamide: IOP-lowering effect in open-angle glaucoma. [2001.02]
A comparison of dorzolamide-timolol combination versus the concomitant drugs. [2000.12]
Effect of timolol, latanoprost, and dorzolamide on circadian IOP in glaucoma or ocular hypertension. [2000.08]
Comparison of the efficacy of betaxolol-brinzolamide and timolol-dorzolamide as suppressors of aqueous humor flow in human subjects. [2000.02]
Comparison of latanoprost monotherapy to dorzolamide combined with timolol in patients with glaucoma and ocular hypertension.A 3-month randomised study. [2000.01]
A randomized trial in patients inadequately controlled with timolol alone comparing the dorzolamide-timolol combination to monotherapy with timolol or dorzolamide. [1999.12]
The dorzolamide/timolol combination versus timolol plus pilocarpine: patient preference and impact on daily life. United States Patient Preference Study Group. International Patient Preference Study Group. [1999.10]
Comparison of dorzolamide and pilocarpine as adjunctive therapy in patients with open-angle glaucoma and ocular hypertension. [1999.09]
A comparison of the efficacy and tolerability of dorzolamide and acetazolamide as adjunctive therapy to timolol. Oral to Topical CAI Study Group. [1998.12]
Comparison of the safety and efficacy of the fixed combination of dorzolamide/timolol and the concomitant administration of dorzolamide and timolol: a clinical equivalence study. International Clinical Equivalence Study Group. [1998.11]
A randomized trial in patients inadequately controlled with timolol alone comparing the dorzolamide-timolol combination to monotherapy with timolol or dorzolamide. Dorzolamide-Timolol Combination Study Group. [1998.10]
A randomized trial comparing the dorzolamide-timolol combination given twice daily to monotherapy with timolol and dorzolamide. Dorzolamide-Timolol Study Group. [1998.10]
The efficacy and safety of the dorzolamide-timolol combination versus the concomitant administration of its components. Dorzolamide-Timolol Study Group. [1998.10]
A double-masked, randomized, 1-year study comparing the corneal effects of dorzolamide, timolol, and betaxolol. Dorzolamide Corneal Effects Study Group. [1998.08]
The efficacy and safety of dorzolamide as adjunctive therapy to timolol maleate gellan solution in patients with elevated intraocular pressure. Additivity Study Group. [1998.08]
A multicenter study comparing dorzolamide and pilocarpine as adjunctive therapy to timolol: patient preference and impact on daily life. [1998.07]
Comparison of dorzolamide and timolol as suppressors of aqueous humor flow in humans. [1997.11]
A comparison of dorzolamide and timolol in patients with pseudoexfoliation and glaucoma or ocular hypertension. [1997.01]
Dorzolamide versus pilocarpine as adjunctive therapies to timolol: a comparison of patient preference and impact on daily life. [1996.09]
The use of dorzolamide and pilocarpine as adjunctive therapy to timolol in patients with elevated intraocular pressure. The Dorzolamide Additivity Study Group. [1996.08]
A six-week dose-response study of the ocular hypotensive effect of dorzolamide with a one-year extension. Dorzolamide Dose-Response Study Group. [1996.08]
A controlled clinical trial of dorzolamide: a single-centre subset of a multicentre study. [1996.02]
A double-masked, randomized 1-year study comparing dorzolamide (Trusopt), timolol, and betaxolol. International Dorzolamide Study Group. [1995.08]
Well-designed clinical trials possibly related to Cosopt (Dorzolamide / Timolol Ophthalmic)
[Structural and immunohistochemical changes of conjunctiva induced by topical glaucoma medication] [2004]
[Prevention of early postoperative increase in intraocular pressure after phacoemulsification. Comparison of different antiglaucoma drugs] [2001.10]
Treatment of intraocular pressure elevation after photorefractive keratectomy. [2001.07]
Clinical efficacy and safety of brinzolamide (Azopt), a new topical carbonic anhydrase inhibitor for primary open-angle glaucoma and ocular hypertension. Brinzolamide Primary Therapy Study Group. [1998.09]
A clinical trial of MK-507, Trusopt, for raised intraocular pressure--the Australian experience. [1996.05]
Relating spontaneous adverse experience reports to scores on a questionnaire querying tolerability. [1995.11]
Other research related to Cosopt (Dorzolamide / Timolol Ophthalmic)
The effects of dorzolamide 2% and dorzolamide/timolol fixed combination on retinal and optic nerve head blood flow in primary open-angle glaucoma patients. [2008.09]
A comparison of dorzolamide/timolol-fixed combination versus bimatoprost in patients with open-angle glaucoma who are poorly controlled on latanoprost. [2008.08]
Comparison of daytime efficacy and safety of dorzolamide/timolol maleate fixed combination versus latanoprost. [2008.07]
Success rates for switching to dorzolamide/timolol fixed combination in timolol responders who are insufficiently controlled by latanoprost monotherapy. [2008.06]
The effect of a single dose of topical 0.005% latanoprost and 2% dorzolamide/0.5% timolol combination on the blood-aqueous barrier in dogs: a pilot study. [2008.05]
Efficacy of the latanoprost versus timolol/dorzolamide combination therapy in patients with primary open angle glaucoma. [2008.03]
The effects of dorzolamide 2% and dorzolamide/timolol fixed combination on retinal and optic nerve head blood flow in primary open-angle glaucoma patients. [2008.01.18]
Comparison of the effects of dorzolamide-timolol fixed combination and brimonidine on intraocular pressure after phacoemulsification surgery. [2008.01]
Costs and effectiveness of travoprost versus a dorzolamide + timolol fixed combination in first-line treatment of glaucoma: analysis conducted on the United Kingdom General Practitioner Research Database. [2007.12]
Intraocular pressure rise after primary posterior continuous curvilinear capsulorhexis with a fixed dorzolamide-timolol combination Randomized safety study with intraindividual comparison using an angulated and a nonangulated intraocular lens. [2007.10]
Retrobulbar haemodynamic effects of the latanoprost/timolol and the dorzolamide/timolol fixed combinations in newly diagnosed glaucoma patients. [2007.05]
Retrobulbar haemodynamic effects of the latanoprost/timolol and the dorzolamide/timolol fixed combinations in newly diagnosed glaucoma patients. [2007.03.01]
Intraocular pressure lowering effect of dorzolamide/timolol fixed combination in patients with glaucoma who were unresponsive to prostaglandin analogs/prostamides. [2007.03]
Comparison of the efficacy and safety of travoprost with a fixed-combination of dorzolamide and timolol in patients with open-angle glaucoma or ocular hypertension. [2006.09]
A comparison of the effects of 0.005% latanoprost and fixed combination dorzolamide/timolol on retrobulbar haemodynamics in previously untreated glaucoma patients. [2006.01]
Timolol/dorzolamide combination therapy as initial treatment for intraocular pressure over 30 mm Hg. [2005.08]
Topically administered timolol and dorzolamide reduce intraocular pressure and protect retinal ganglion cells in a rat experimental glaucoma model. [2005.04]
[IOP in rabbits after instillation of a mixture of the antiglaucomatic Cosopt and the aminoacid L-argininin HCL into the conjunctival sac] [2005.01]
Hypotony and choroidal effusion induced by topical timolol and dorzolamide in patients with previous glaucoma drainage device implantation. [2003.11]
Experience with Cosopt, the fixed combination of timolol and dorzolamide, after switch from free combination of timolol and dorzolamide, in Swiss ophthalmologists' offices. [2003]
Experience with COSOPT, the fixed combination of timolol and dorzolamide, gained in Swiss ophthalmologists' offices. [2003]
Comparison of the ocular hypotensive effect of brimonidine, dorzolamide, latanoprost, or artificial tears added to timolol in glaucomatous monkey eyes. [2000.12]
[Pharmacological profiles of the potent carbonic anhydrase inhibitor dorzolamide hydrochloride, a topical antiglaucoma agent] [2000.06]
Two-year safety study of dorzolamide as monotherapy and with timolol and pilocarpine. Dorzolamide Safety Study Group. [1998.12]
Additive effect of dorzolamide on aqueous humor flow in patients receiving long-term treatment with timolol. [1998.11]
Influence of dorzolamide on corneal thickness, endothelial cell count and corneal sensibility. [1998.02]
Dorzolamide. A review of its pharmacology and therapeutic potential in the management of glaucoma and ocular hypertension. [1997.05]
The preclinical pharmacology of dorzolamide hydrochloride, a topical carbonic anhydrase inhibitor. [1996.09]
Other possibly related research studies
Cost considerations of the new fixed combinations for glaucoma medical therapy. [2005.06]
The effect of combination pharmacotherapy on the prescription trends of glaucoma medications. [2005.04]
Is addition of a third or fourth antiglaucoma medication effective? [2004.04]
Medical therapy cost considerations for glaucoma. [2003.07]
Cost analysis of glaucoma medications: a 3-year review. [2002.08]
Water-drinking test in patients with primary open-angle glaucoma while treated with different topical medications. [2005.06]
Intraocular pressure lowering efficacy of travoprost. [2004.09]
Alphagan allergy may increase the propensity for multiple eye-drop allergy. [2005.02]
Corneal and conjunctival changes caused by commonly used glaucoma medications. [2004.07]
Fixed combinations of topical glaucoma medications. [2004.04]
Observed time between prescription refills for newer ocular hypotensive agents: the effect of bottle size. [2004.01]
Patient persistency with topical ocular hypotensive therapy in a managed care population. [2004.01]
Ocular factors relevant to anti-glaucomatous eyedrop-related keratoepitheliopathy. [2003.12]
Prescription of topical antiglaucoma agents for patients with contraindications to beta-blockers. [2003.10]
Brinzolamide : a review of its use in the management of primary open-angle glaucoma and ocular hypertension. [2003]
Four years later: a clinical update on latanoprost. [2003.03]
An update on bimatoprost in glaucoma therapy. [2002.12]
Primary glaucoma in Burmese cats. [2002.11]
The effect of latanoprost on circadian intraocular pressure. [2002.08]
Topical bimatoprost: a review of its use in open-angle glaucoma and ocular hypertension. [2002]
Effects of topical antiglaucoma eye drops on prostaglandin E(2)-induced aqueous flare elevation in pigmented rabbits. [2002.04]
|
